ArticleBiology open2015
Generation of tissue-engineered small intestine using embryonic stem cell-derived human intestinal organoids.
Article in Biology open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed.
- Biological Insights into Intestinal Adaptation from Preclinical Models of Short Bowel Syndrome.Cells · 2026Review
- Autogenic-regenerated intestinal transplantation improves outcomes in short bowel syndrome.JCI insight · 2026Article
- Alternatives to animal models in gastroenterology and hepatology research.Frontiers in pharmacology · 2026Review
- Development of a novel tubular scaffold for tissue-engineered small intestine.Journal of pediatric surgery · 2026Article
- Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025Review
- Norovirus replication, host interactions and vaccine advances.Nature reviews. Microbiology · 2025Review
- Innervation of Human Intestinal Organoids.Journal of visualized experiments : JoVE · 2025Article
- Standardization and consensus in the development and application of bone organoids.Theranostics · 2025Review
- Application of Polyglycolic Acid/Poly (Lactic-co-glycolic Acid) in Thread Embedding Acupuncture for Obesity: New Strategies and Challenges.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Review
- Bioengineering of Intestinal Grafts.Gastroenterology clinics of North America · 2024Review
- Tissue engineering and regenerative medicine approaches in colorectal surgery.Annals of coloproctology · 2024Review
- Engineered Synthetic Matrices for Human Intestinal Organoid Culture and Therapeutic Delivery.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction.Biomaterials research · 2024Review
- Potential Application of Intestinal Organoids in Intestinal Diseases.Stem cell reviews and reports · 2024Review
- Engineered organoids for biomedical applications.Advanced drug delivery reviews · 2023Review
- Liver organoid culture methods.Cell & bioscience · 2023Review
- Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.Cancer medicine · 2023Review
- Engineered biomaterials in stem cell-based regenerative medicine.Life medicine · 2023Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Short bowel syndrome (SBS) is characterized by poor nutrient absorption due to a deficit of healthy intestine. Current treatment practices rely on providing supportive medical therapy with parenteral nutrition; while life saving, such interventions are not curative and are still associated with significant co-morbidities. As approaches to lengthen remaining intestinal tissue have been met with only limited success and intestinal transplants have poor survival outcomes, new approaches to treating SBS are necessary. Human intestine derived from embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs), called human intestinal organoids (HIOs), have the potential to offer a personalized and scalable source of intestine for regenerative therapies. However, given that HIOs are small three-dimensional structures grown in vitro, methods to generate usable HIO-derived constructs are needed. We investigated the ability of hESCs or HIOs to populate acellular porcine intestinal matrices and artificial polyglycolic/poly L lactic acid (PGA/PLLA) scaffolds, and examined the ability of matrix/scaffolds to thrive when transplanted in vivo. Our results demonstrate that the acellular matrix alone is not sufficient to instruct hESC differentiation towards an endodermal or intestinal fate. We observed that while HIOs reseed acellular porcine matrices in vitro, the HIO-reseeded matrices do not thrive when transplanted in vivo. In contrast, HIO-seeded PGA/PLLA scaffolds thrive in vivo and develop into tissue that looks nearly identical to adult human intestinal tissue. Our results suggest that HIO-seeded PGA/PLLA scaffolds are a promising avenue for developing the mucosal component of tissue engineered human small intestine, which need to be explored further to develop them into fully functional tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.